Compare MATV & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATV | CTMX |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.4M | 596.2M |
| IPO Year | 1995 | 2015 |
| Metric | MATV | CTMX |
|---|---|---|
| Price | $12.20 | $3.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $10.00 | $6.50 |
| AVG Volume (30 Days) | 371.8K | ★ 3.4M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | ★ $1,982,500,000.00 | $113,631,000.00 |
| Revenue This Year | $3.68 | N/A |
| Revenue Next Year | $2.82 | N/A |
| P/E Ratio | ★ N/A | $15.86 |
| Revenue Growth | ★ 0.39 | N/A |
| 52 Week Low | $4.34 | $0.40 |
| 52 Week High | $13.57 | $4.62 |
| Indicator | MATV | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 49.88 |
| Support Level | $11.52 | $3.42 |
| Resistance Level | $13.19 | $4.33 |
| Average True Range (ATR) | 0.50 | 0.29 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 38.54 | 38.54 |
Mativ Holdings Inc is a diversified producer of premium specialty papers and resin-based products. It manufactures and sells paper and reconstituted tobacco products to the tobacco industry as well as specialized paper products. The company operates in two segments namely Advanced Materials and Structures, which manufactures resin-based products used in specialty applications in the filtration, infrastructure and construction, transportation, industrial, and medical end-markets, and Engineered Papers, which produces cigarette papers and reconstituted tobacco products for cigarette and cigar manufacturers, as well as various other non-tobacco paper products.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.